I cannot wait until I can retire with enough cash stored under my mattress.
But first! Dendreon presented the IMPACT data yesterday and it pretty much validated everything they said about Provenge. Longer survival. In a patient population where the average placebo life expectancy was 21.7 months, Provenge conferred an extra 4.1 months... nearly 20% longer life. And at the 3 year mark, 38% of Provenge patients were still alive versus only 21% of placebo.
In the 93 seconds before trading was halted before the data presentation, the share price was manipulated down from $25 to $7.50, closing before halt at $11 something! A lot of short-sellers managed to cover at a good price. Investing primarily in micro and small cap biotechs as I do, I wish I could say this was extra-ordinary but ... it isn't. The SEC needs to do it's job and stop this crap from happening.
It's a great day for prostate cancer patients. Congratulations to Dendreon!
Regards,
Trond
Subscribe to:
Post Comments (Atom)
1 comment:
Curious on your opinon on our move towards Socialism.
Post a Comment